Drugmakers bulk up with bets on weight-loss treatments
Send a link to a friend
[May 15, 2023]
(Reuters) - Zealand Pharma and partner Boehringer Ingelheim on
Wednesday announced positive trial data for their weight-loss treatment
and joined the race for a share of a global obesity drug market that is
expected to touch $100 billion within a decade.
More than half a dozen companies are developing weight-loss therapies
similar to Novo Nordisk's Wegovy, with Eli Lilly and Co's tirzepatide
widely expected to be the next to hit the market.
The following is a list of companies targeting the next big blockbuster
opportunity:
NOVO NORDISK
Novo Nordisk's weekly injection Wegovy was approved in 2021. It works by
mimicking a hormone called glucagon-like peptide-1 (GLP-1) that triggers
the feeling of fullness in the body after eating.
The company also had an older product Saxenda, approved in 2014, but
Wegovy is considered safer and more effective.
Novo said last week it would have to halve the supply of starter doses
of Wegovy in the U.S. to cope with high demand.
ELI LILLY
Eli Lilly said last month its diabetes treatment Mounjaro helped people
with type 2 diabetes who were also obese or overweight to lose nearly
16% of their body weight in a large trial.
The drug, also known as tirzepatide, is expected to receive a U.S.
approval for weight loss later this year.
Tirzepatide activates the body's receptors for gastric inhibitory
polypeptide (GIP) and GLP-1, which are natural hormones and found in
areas of the brain important for appetite regulation.
![](http://archives.lincolndailynews.com/2023/May/15/images/ads/current/graue_sda_PROMGRAD_2023.png)
PFIZER
Pfizer Inc and Japanese partner Sosei Heptares' experimental oral GLP-1
drug, PF-07081532, is being tested in a mid-stage trial to treat type 2
diabetes and obesity.
The company said it plans to enroll some patients in its late-stage
trial who have already used Wegovy or Mounjaro to show they can
effectively switch to Pfizer's oral alternative.
AMGEN
Amgen Inc's experimental obesity drug, AMG133, showed promising
durability trends in an early-stage trial late last year.
The drug candidate showed mean weight loss of 14.5% after 12 weeks of
treatment at the highest monthly dose. It has a dual mechanism which
targets GLP-1 and GIP.
[to top of second column]
|
![](../images/051523PIX/health27.jpg)
A player is pictured during his "Futbol
de Peso" (Soccer of Weight ) league soccer match, a league for obese
men who want to improve their health through soccer and nutritional
counseling, in San Nicolas de los Garza, Mexico, September 16, 2017.
REUTERS/Daniel Becerril/File Photo
![](http://archives.lincolndailynews.com/2019/Sep/05/images/ads/current/stclara_lda_SPONSOR_090519.png) The company said it plans a larger
mid-stage study this year.
ALTIMMUNE
Altimmune Inc in March said its experimental obesity drug,
pemvidutide, helped reduce weight by over 10% on average in a
mid-stage trial.
However, the drug candidate also showed safety concerns with
patients experiencing nausea and vomiting of mild and moderate
severity.
Pemvidutide is a dual action drug that targets GLP-1 and also
imitates another gut hormone called glucagon, which helps burn more
fat when exercising and prevents the harmful build-up of fat in the
liver.
VIKING THERAPEUTICS
Viking Therapeutics Inc's experimental obesity drug, VK2735, showed
up to 6% reduction in mean weight in an early-stage study.
The company plans to test higher doses of the drug over a longer
treatment window in a mid-stage trial and expects results from an
early-stage extension study to evaluate oral doses by the middle of
the year.
VK2735 is also a dual action drug that targets both GLP-1 and GIP
receptors.
ZEALAND PHARMA
Denmark's Zealand Pharma and Boehringer Ingelheim's experimental
obesity treatment achieved up to 14.9% weight loss in a mid-stage
trial on Wednesday.
The drug candidate, BI 456906, also targets GLP-1 and GIP receptors.
OPKO HEALTHOpko Health has completed a mid-stage trial of its
obesity drug, pegapamodutide, that it expects will have fewer side
effects. The current GLP-1 drugs can cause nausea and vomiting.
China's LeaderMed has agreed to develop and sell Opko's compound in
the country. The company is also in talks with larger drugmakers in
Western countries for a partnership.
(Reporting by Mariam Sunny and Pratik Jain in Bengaluru; Editing by
Sriraj Kalluvila)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |